#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI) (now called Innovative Health Initiative, IHI) of the European Commission and is currently running two projects: HARMONY (January 2017-June 2023) and HARMONY PLUS (October 2020-September 2023). In addition to the research projects that exploit the HARMONY Big Data Platform, the HARMONY Alliance is running Delphi surveys to develop core outcome sets (COS) for HMs, as well as Health Technology Assessment projects and multi-stakeholder activities.

EHA is one of the founding Partners and has an active role in multiple projects and activities.
www.harmony-alliance.eu| www.bigdataforbloodcancer.eu

European Reference Networks (ERNs), an initiative of the European Commission, aim to improve the quality, safety of, and access to, treatments of complex or rare diseases by pooling knowledge and resources. Launched in early 2017, EuroBloodNet (European Reference Network for rare hematological diseases) results from joint efforts of the EHA and the European Network for Rare Congenital Anemias (ENERCA).

The network brings together 66 highly specialized hospital centers with expertise on malignant and non-malignant rare hematological diseases. As in other ERNs, significant patient involvement is a key feature of EuroBloodNet.

EHA is a partner in the PROFILE project, an EU (Horizon 2020) funded 'Innovative Training Network' geared towards the stratification of patients with the rare autoimmune disorder Thrombotic Thrombocytopenic Purpura (TTP).

Stratifying acquired TTP patients by understanding disease pathology, using new types of biomarkers, and predicting their risk for relapse will be crucial for treatment adjustment in these patients and development of personalized medicine in the future.

The joint doctoral training (European Industrial Doctorate) provided by the academic and corporate partners in PROFILE allows PhD students to develop skills inside and outside academia that respond to public and private sector needs.